Canaccord Genuity Group Cuts Artivion (NYSE:AORT) Price Target to $48.00

Artivion (NYSE:AORT) had its price objective cut by Canaccord Genuity Group from $51.00 to $48.00 in a report released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts also recently issued reports on the company. Wall Street Zen downgraded Artivion from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 24th. Needham & Company LLC reissued a “buy” rating and issued a $58.00 price objective on shares of Artivion in a report on Monday, February 2nd. Oppenheimer reaffirmed an “outperform” rating and issued a $50.00 target price on shares of Artivion in a report on Friday, November 7th. Citizens Jmp upped their price target on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, January 21st. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $48.69.

Artivion Price Performance

Shares of NYSE:AORT opened at $36.24 on Friday. The company’s fifty day moving average price is $43.60 and its 200 day moving average price is $42.95. Artivion has a 12 month low of $21.97 and a 12 month high of $48.25. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62. The firm has a market capitalization of $1.72 billion, a P/E ratio of 181.18 and a beta of 1.59.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.03. The company had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The business’s quarterly revenue was up 19.2% compared to the same quarter last year. As a group, sell-side analysts predict that Artivion will post 0.37 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Artivion news, CAO Amy Horton sold 4,572 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $44.42, for a total transaction of $203,088.24. Following the completion of the transaction, the chief accounting officer owned 130,058 shares in the company, valued at approximately $5,777,176.36. This represents a 3.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James P. Mackin sold 30,921 shares of the business’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $45.56, for a total transaction of $1,408,760.76. Following the sale, the chief executive officer directly owned 800,993 shares in the company, valued at approximately $36,493,241.08. This represents a 3.72% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 109,660 shares of company stock worth $4,941,347 in the last ninety days. Insiders own 8.10% of the company’s stock.

Institutional Investors Weigh In On Artivion

A number of institutional investors and hedge funds have recently modified their holdings of AORT. Caitong International Asset Management Co. Ltd acquired a new position in Artivion during the third quarter worth $27,000. Aster Capital Management DIFC Ltd increased its position in shares of Artivion by 402.3% in the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after buying an additional 519 shares in the last quarter. Larson Financial Group LLC raised its stake in shares of Artivion by 148.5% during the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after buying an additional 563 shares during the last quarter. USA Financial Formulas boosted its position in shares of Artivion by 163.5% in the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after buying an additional 703 shares in the last quarter. Finally, KBC Group NV acquired a new stake in Artivion in the 4th quarter valued at about $65,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

Key Stories Impacting Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q4 beat — Artivion reported Q4 EPS of $0.17 versus the $0.14 consensus and revenue of $118.3M (above estimates), with quarterly revenue up ~19% year-over-year. This confirms continued top-line momentum. Read More.
• Positive Sentiment: Full-year revenue growth — GAAP revenue rose to $441.3M for FY2025 from $388.5M in FY2024, signaling sustained recovery/expansion in sales. Read More.
• Positive Sentiment: FY2026 revenue guidance modestly above street — management guided revenue to $486.0M–$504.0M (consensus ~$491.1M), which implies a midpoint slightly ahead of estimates and supports continued top-line growth. Read More.
• Neutral Sentiment: Earnings call materials/transcript posted — the full Q4 earnings call transcript and slide deck are available for detail on segment performance and cadence. Useful for investors wanting management color. Read More.
• Negative Sentiment: Analyst price-target trim — Canaccord cut its AORT price target from $51 to $48 while keeping a “buy” rating; the cut reduces near-term analyst upside and may have pressured sentiment. Read More.
• Negative Sentiment: EPS guidance unclear/omitted — the company’s release/summary lacked clear EPS guidance (the EPS figure was not provided in the guidance summary), which can create uncertainty even with revenue guidance in place. Read More.
• Negative Sentiment: Large-volume sell-off — shares moved lower on unusually high volume versus average, indicating stronger selling pressure that amplified the price reaction to mixed news. Read More.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.